ESMO Solid Tumors 2022 – Stacey A. Cohen
Stacey A. Cohen explains if ctDNA can detect MRD and predict recurrence in patients with colon cancer in a real-world setting, if it should be used in daily clinical practice or as a surveillance biomarker in stage II ctDNA-negative colon cancer patients. Moreover, she depicts how the treatment of patients with colon cancer might change in the foreseeable future.
Here is the full ESMO 2022 Solid Tumors report.
More posts
Promising therapeutic strategies for colorectal cancer treatment
Promising therapeutic strategies for colorectal cancer treatment With more than
From neoadjuvant to second-line therapeutic options for RCC patients
From neoadjuvant to second-line therapeutic options for RCC patients Kidney can
Towards treating all stages of gastric cancer and gastroesophageal junction adenocarcinoma
Towards treating all stages of gastric cancer and gastroesophageal junction adenoca
Update on the treatment for advanced HCC
Update on the treatment for advanced HCC With more than 900,000 newly diagnosed
New clinical insights in head and neck squamous cell carcinoma
New clinical insights in head and neck squamous cell carcinoma Head and neck squamous c
Preface – ESMO Solid Tumor 2022
Preface – ESMO Solid Tumors 2022 © privat - Jaime R. Merchan, MD. MMSc, University of
